We've been had. The SEC FDA and FBI aren't interested.
"Relypsa and Vifor Fresenius Medical Care Renal Pharma Enter Into Partnership to Commercialize Patiromer FOS in Europe and Additional Territories"
Fresenius the dialysis centers where patients died? Was there any investigation into their responsibility for the deaths?
Will patients be informed Patiromer is brought to them by the same people who brought them Omontys?
And now the former Affymax board and execs enjoy a new relationship with their old buddies at Fresenius.
Please note the insiders (including Orwin and ORBIMED) are selling shares in Relypsa too.
I expect we might all be disappointed by the time Mr. Couchman is through with us. He still hasn't answered questions posed last December including procedures for nominating board members. When the former board announced Couchman's new positions they also resigned leaving how many board members?
Mr. Coachman is the CEO but not the owner of Affymax. He was elected by the former board members. Besides his position in the company, he is a stockholder, probably with more shares than you and me. If you are not satisfied with his leadership, you can ask your supporters to vote him down. In this case, we should have a special stockholder meeting.
I bought a whole piece of watermelon but I could not consume it. So, I left the rest for a while. When I ate it again, it tasted a little bit different from the fresh one. Then I decided to buy watermelon cuts so that I can eat all.
It is cheaper to use multiple-use vials than single-use vials. However, the former creates an uncertainty: contamination with microbes. In order to prevent the contamination, the manufacture added preservatives in the vials. Did the manufacture tested whether the preservatives affect the efficacy and safety of Omontys?
I don’t understand why Affymax and Takeda applied multiple-use vials containing preservatives during the pilot introduction of omontys instead of sticking to single –use vials applied in the phase III trial (please see NEJM, 2014). Changing conditions without a proper experiment(s) should be avoided.
In Affy's case, absolutely. Nonetheless, Omontys adverse incidents were off the charts, especially "unexplained" deaths, compared to industry standards.
Like the pathetic "company" AFFY turned out to be, this board too is on the verge of being shut down. Do it YAPOO!. End the nightmare!
Sell this garbage and move on. Buy AMBA and recover your losses by the EOY. Use your losses in AFFY to offset SOME of your GAINS with AMBA.
You can thank me later.